TARSUS PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings
TARSUS PHARMACEUTICALS, INC. (TARS) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings of -$201.00 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2024-05-08.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 · last filed 2024-05-08
- TARSUS PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2023-09-30 was -$201.00K.
- TARSUS PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2023-06-30 was $18.00K.
- TARSUS PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2023-03-31 was -$17.00K.
- TARSUS PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2022-09-30 was -$18.00K.
- TARSUS PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2022 was $103.00K, a 93.09% decline from fiscal 2021.
- TARSUS PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2021 was $1.49M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 3 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|---|
| 2023-09-30 | -$201.00K 10-Q · filed 2024-05-08 | -$36.00K 10-Q · filed 2023-11-09 | -$183.00K derived: sum of 2 quarters · filed 2024-05-08 | -$200.00K derived: sum of 3 quarters · filed 2024-05-08 | |
| 2023-06-30 | $18.00K 10-Q · filed 2023-11-09 | $1.00K derived: sum of 2 quarters · filed 2024-05-08 | |||
| 2023-03-31 | -$17.00K 10-Q · filed 2024-05-08 | ||||
| 2022-12-31 | $103.00K 10-K · filed 2023-03-17 | ||||
| 2022-09-30 | -$18.00K 10-Q · filed 2023-11-09 | -$275.00K derived: sum of 2 quarters · filed 2023-11-09 | -$520.00K derived: sum of 3 quarters · filed 2023-11-09 | ||
| 2022-06-30 | -$257.00K 10-Q · filed 2023-11-09 | -$502.00K derived: sum of 2 quarters · filed 2023-11-09 | |||
| 2022-03-31 | -$245.00K 10-Q · filed 2023-11-09 | ||||
| 2021-12-31 | $1.49M 10-K · filed 2023-03-17 | ||||
| 2021-03-31 | $1.23M 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |